SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

25-year-old AI investor’s $16 billion bet hits a brutal reality check

Israel’s cyber industry bets identity will become the next AI security battleground

Israeli startups raised $1.5 billion in July as investors doubled down on enterprise AI

Why Israel may need to take its most secret missile maker public

Buzz

Most popular

Daily

Weekly

1

Israel searches for technology that could find soldiers and pilots who cannot call for help

2

Another 10 U.S. tankers are headed to Israel's Ben Gurion as airport delays mount

3

After IAI and Rafael, secretive missile engine maker Tomer moves toward an IPO

4

ServiceNow continues layoffs as it restructures around AI

5

Israel's Iron Dome and Arrow makers unlikely to reach the IPO market before 2027 as Tomer joins the queue

Generics

6 stories about Generics

קור שולץ מנכ"ל טבע 9.11.19

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself

11.11.19|Uri Tal-Tene

With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year

ה מטה הנוכחי של טבע ב ארה"ב

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer

Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800

קאר שולץ מנכל טבע

Teva to Relocate U.S. Headquarters to New Jersey

08.07.18|Lilach Baumer

In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt

קאר שולץ מנכל טבע

Goldman Sachs Sees 16% Upside in Teva Stock

26.06.18|Dror Reich

Following a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price

יו"ר ועד עובדי טבע כפר סבא אלירן קוזליק

In Protest of New Bonus Plan, Teva Sued by Israeli Employees

15.03.18|Dror Reich

After announcing the cancellation of its annual bonuses for 2017 due to debt, the Israel-based drugmaker rolled out a performance-based bonus scheme for 2018 in February

מנכ"ל טבע גנריקה סיגורדור סיגי אולפסון

Drugmaker Hikma Appoints Former Teva Executive as CEO

20.02.18|Asaf Shalev

The appointment of Sigurdur Olafsson comes as Hikma has been struggling to bolster the performance of its generic drugs unit